These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34316024)

  • 21. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.
    Ivgy-May N; Hajak G; van Osta G; Braat S; Chang Q; Roth T
    J Clin Sleep Med; 2020 Sep; 16(9):1455-1467. PubMed ID: 32351205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Controlled Trial of Melatonin for Sleep Disturbance in Dravet Syndrome: The DREAMS Study.
    Myers KA; Davey MJ; Ching M; Ellis C; Grinton BE; Roten A; Lightfoot PA; Scheffer IE
    J Clin Sleep Med; 2018 Oct; 14(10):1697-1704. PubMed ID: 30353809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM
    CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep Complaints and the 24-h Melatonin Level in Individuals with Smith-Magenis Syndrome: Assessment for Effective Intervention.
    Spruyt K; Braam W; Smits M; Curfs LM
    CNS Neurosci Ther; 2016 Nov; 22(11):928-935. PubMed ID: 27743421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sleep disorders in children with Angelman and Smith-Magenis syndromes: The assessment of potential causes of disrupted settling and night time waking.
    Agar G; Oliver C; Trickett J; Licence L; Richards C
    Res Dev Disabil; 2020 Feb; 97():103555. PubMed ID: 31838315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individuals with Smith-Magenis syndrome display profound neurodevelopmental behavioral deficiencies and exhibit food-related behaviors equivalent to Prader-Willi syndrome.
    Alaimo JT; Barton LV; Mullegama SV; Wills RD; Foster RH; Elsea SH
    Res Dev Disabil; 2015 Dec; 47():27-38. PubMed ID: 26323055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study.
    Roth T; Lankford DA; Bhadra P; Whalen E; Resnick EM
    Arthritis Care Res (Hoboken); 2012 Apr; 64(4):597-606. PubMed ID: 22232085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
    Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
    Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
    Hirschfeld RM; Eerdekens M; Kalali AH; Canuso CM; Khan AA; Karcher K; Palumbo JM
    Int Clin Psychopharmacol; 2006 Jan; 21(1):11-20. PubMed ID: 16317312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
    Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
    Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct assessment of overnight parent-child proximity in children with behavioral insomnia: Extending models of operant and classical conditioning.
    Agar G; Oliver C; Richards C
    Behav Sleep Med; 2023; 21(3):254-272. PubMed ID: 35796281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder.
    Gringras P; Nir T; Breddy J; Frydman-Marom A; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2017 Nov; 56(11):948-957.e4. PubMed ID: 29096777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cross-syndrome cohort comparison of sleep disturbance in children with Smith-Magenis syndrome, Angelman syndrome, autism spectrum disorder and tuberous sclerosis complex.
    Trickett J; Heald M; Oliver C; Richards C
    J Neurodev Disord; 2018 Mar; 10(1):9. PubMed ID: 29490614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
    Chang YS; Lin MH; Lee JH; Lee PL; Dai YS; Chu KH; Sun C; Lin YT; Wang LC; Yu HH; Yang YH; Chen CA; Wan KS; Chiang BL
    JAMA Pediatr; 2016 Jan; 170(1):35-42. PubMed ID: 26569624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty-four-hour motor activity and body temperature patterns suggest altered central circadian timekeeping in Smith-Magenis syndrome, a neurodevelopmental disorder.
    Smith ACM; Morse RS; Introne W; Duncan WC
    Am J Med Genet A; 2019 Feb; 179(2):224-236. PubMed ID: 30690916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up.
    Weiss MD; Surman C; Khullar A; Owens J; He E; Cataldo M; Donnelly G
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):623-630. PubMed ID: 34714112
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
    Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smith-Magenis syndrome and its circadian influence on development, behavior, and obesity - own experience.
    Chen L; Mullegama SV; Alaimo JT; Elsea SH
    Dev Period Med; 2015; 19(2):149-56. PubMed ID: 26384114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smith-Magenis syndrome: Clinical and behavioral characteristics in a large retrospective cohort.
    Rive Le Gouard N; Jacquinet A; Ruaud L; Deleersnyder H; Ageorges F; Gallard J; Lacombe D; Odent S; Mikaty M; Manouvrier-Hanu S; Ghoumid J; Geneviève D; Lehman N; Philip N; Edery P; Héron D; Rastel C; Chancenotte S; Thauvin-Robinet C; Faivre L; Perrin L; Verloes A
    Clin Genet; 2021 Apr; 99(4):519-528. PubMed ID: 33368193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.